Studies, Education, and Key Opinion Leaders' Presentations at SAWC Demonstrate Clinical Efficacy of MiMedx EpiFix

MARIETTA, Ga., Sept. 18, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that  presentations and abstracts demonstrating the clinical efficacy of EpiFix® are being presented at the Symposium on Advanced Wound Care (SAWC) Fall 2015 meeting. The SAWC Fall Symposium will be held in Las Vegas, Nevada, beginning on September 26, 2015 and concluding on September 28, 2015.

Thirteen abstracts demonstrating the healing results of MiMedx EpiFix and AmnioFix® dehydrated human amnion/chorion membrane (dHACM) allografts in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PUs), and extensive life threatening wounds will be presented at SAWC. In addition, MiMedx will host a symposium, conduct presentations and provide in-booth education during the three day event. During the symposium, presentations and education sessions, Key Opinion Leaders will speak on their professional experiences using MiMedx dHACM allografts in the treatment of chronic, complex and extreme wounds.

"The fall and spring symposiums of the SAWC are the leading national wound healing conferences, and we are very pleased to be expanding the MiMedx presence at the upcoming SAWC Fall Symposium," said Parker H. "Pete" Petit, MiMedx Chairman and CEO.  "We are proud of our efforts in evidencing the scientific foundation and clinical results of our allografts and are committed to continuing our aggressive pace of clinical and scientific studies and facilitating their publication in leading peer-reviewed journals. The SAWC is a superb forum for the healthcare industry to present the science of breakthrough technologies and products and we appreciate the opportunity to play an expanded role in delivering evidenced-based medicine to the thought leaders and others attending the SAWC."

The EpiFix poster, "The Role of Skin Substitutes in Complex Scalp Reconstruction in an Era of Free Tissue Transfer," authored by John Ko, MD, is the highest scoring poster abstract in the SAWC Case Series/Study category.

The numerous abstracts presenting EpiFix® studies and cases include:

• "Dehydrated Human Amnion/Chorion Membrane Allograft as a Treatment for Stage IV Pressure Ulcers" (Abstract # CS-011);
• "Pathologic Changes Observed with use of Micronized Dehydrated Human Amnion/Chorion Membrane Injections after Surgical Excision of Plantar Fibromatosis: a Unique Case Study" (Abstract # CS-023);
• "Use of Dehydrated human Amnion/Chorion Membrane Mesh Allograft in Wounds with Exposed Bone or Tendon" (Abstract # CS-048);
• "Dehydrated Human Amnion/Chorion Membrane as Adjunctive Therapy in the Treatment of Pyoderma Gangrenosum: A Case Report" (Abstract # CS-099);  
• "Clinical Factors and Cost Effectiveness Associated with Healing of Venous Leg Ulcers with Dehydrated Human Amnion/Chorion Membrane Allografts" (Abstract # CR-027);
• "Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity in Vitro" (Abstract # LR-013);
• "Type I and II Diabetic Adipose Derived Stem Cells Respond In Vitro to Dehydrated Human Amnion/Chorion Membrane Allograft Treatment by Increasing Proliferation, Migration, and Altering Cytokine Secretion" (Abstract # LR-01);
• "Description of Technique for Implantation of Dehydrated Human Amnion/Chorion Membrane Allograft for the Treatment of Plantar Fasciitis" (Abstract # IR-023);
• "Does Application of Dehydrated Human Amnion/Chorion Membrane (DHACM) Increase Matrix Metalloproteinase Levels in Wounds" (Abstract # LB-016);
• "Human Amniotic Membrane Allograft to Treat Wounds with Exposed Bone and Tendon" (Abstract # CS-080);
• "Powderized Injectable Dehydrated Human Amniotic/Chorionic Membrane to Heal Tunneling Diabetic Foot Wounds" (Abstract # CS-081);
• "The Role of Skin Substitutes in Complex Scalp Reconstruction in an Era of Free Tissue Transfer" (Abstract # CS-061); and
• "The Use of Human Amniotic Chorion Membrane Allograft for Complex Hand Reconstruction and Limb Salvage" (Abstract # CS-051).

MiMedx will host a Breakfast Symposium on September 26^th from 7:30AM to 9:00AM. Jeffrey Frenchman, DPM; Thomas Serena, MD; and John Ko, MD will speak on "The Dynamic Impact of EpiFix: A Bioactive Tissue Matrix for the Treatment of Chronic & Complex Wounds." At the evening dinner presentation hosted by MiMedx on September 26th at 8:00pm, John Ko, MD, and Thomas Davenport, MD, will speak on "Complex Wounds and How to Approach Them Using EpiFix."

MiMedx is exhibiting at the conference (booth #301). On September 26^th at 6:00PM and September 27^th at 1:30PM, Matthew Garoufalis, DPM, will provide in-booth education on "Multiple Approaches to Wound Closure Utilizing MiMedx Amnion/Chorion Allograft Products."  On September 26^th at 6:45PM and September 27^th at 2:15PM, Thomas Davenport, MD, will present in-booth education on "Extreme Wound Care: The Treatment of Difficult Cases That You Think Will Never Heal."  Booth hours are Saturday, September 26^th from 5:15PM – 7:15PM; Sunday, September 27^th from 12:30PM – 3:00PM; and Monday, September 28^th from 12:30PM – 2:00PM.

About EpiFix

EpiFix is a human amniotic allograft tissue offering uniquely processed through the Company's proprietary PURION® Process. EpiFix dHACM modulates inflammation and reduces scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix^® minimizes graft waste. EpiFix is a minimally manipulated, dehydrated non-variable cellular amniotic membrane allograft that preserves and delivers multiple extracellular matrix proteins, growth factors, cytokines and other specialty proteins present in amniotic tissue to help regenerate soft tissue. The Company's PURION^® Process combines cleaning, dehydration and sterilization, making EpiFix a safe, sterilized tissue that may be stored at ambient conditions for up to 5 years.

About AmnioFix

AmnioFix is a composite amniotic tissue membrane minimally manipulated to protect the collagen matrix and its natural properties. AmnioFix reduces scar tissue formation, modulates inflammation in the surgical site, enhances healing and acts as a barrier. AmnioFix is processed through the proprietary PURION® Process that combines cleaning, dehydration and sterilization, and it may be stored at ambient conditions for up to 5 years. The proprietary PURION® Process protects the delicate scaffold during processing, leaving an intact collagen matrix. The result is a durable graft with natural barrier properties to optimize surgical performance and ease of use. AmnioFix is available in sheet/membrane, particulate, and wrap configurations for use in surgical, soft tissue, tendon, and nerve applications. 

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies are AmnioFix®, EpiFix® and CollaFix™. AmnioFix® and EpiFix® are our tissue technologies processed from human amniotic membrane derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 450,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. CollaFix™, our next technology platform we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.  CollaFix™ is the only biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's commitment to continuing its aggressive pace of clinical and scientific studies and facilitating their publication in leading peer-reviewed journals.  These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Company may not be able to sustain its aggressive pace of clinical and scientific studies and facilitating their publication in leading peer-reviewed journals, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2014 and its most recent Form 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

SOURCE MiMedx Group, Inc.

Related Links

http://www.mimedx.com